siRNA targeting of PRDX3 enhances cisplatin‑induced apoptosis in ovarian cancer cells through the suppression of the NF‑κB signaling pathway

Duan,Jie; Lang,Yan; Song,Chengwen; Xiong,Jun; Wang,Yan; Yan,Yang

doi:10.3892/mmr.2013.1370

siRNA targeting of PRDX3 enhances cisplatin‑induced apoptosis in ovarian cancer cells through the suppression of the NF‑κB signaling pathway

Authors:
- Jie Duan
- Yan Lang
- Chengwen Song
- Jun Xiong
- Yan Wang
- Yang Yan
View Affiliations

Affiliations: Gynecology, Maternal and Child Health Hospital of Hubei Province, Wuhan, Hubei 430070, P.R. China, Wuhan General Hospital of Guangzhou Military, Wuhan, Hubei 430070, P.R. China
Published online on: March 14, 2013 https://doi.org/10.3892/mmr.2013.1370
Pages: 1688-1694

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The overexpression of peroxiredoxins (prxs) has been shown to be associated with the development, progression and drug resistance of cancer. However, the role of the prxs in the drug resistance of ovarian cancer is unknown. The present study aimed to investigate the effect and mechanism of the downregulation of PRDX3 on cisplatin‑induced ovarian cancer cell apoptosis. The expression of PRDX3 in ovarian cancer was examined by immunohistochemistry. The effect on cisplatin‑induced ovarian cancer apoptosis by the silencing of PRDX3 was determined by cell proliferation and colony formation assays and the examination of tumor growth in the nude mice. To further investigate the mechanism behind the downregulation of PRDX3, the expression of the anti‑apoptotic proteins Bcl‑2 and Bcl‑XL and the pro‑apoptotic proteins Bax, Caspase‑3 and Caspase‑9 was examined in various ovarian cancer cells. The results showed that the aberrant expression of PRDX3 in ovarian cancer may be a factor responsible for its progression. SKOV3 ovarian cancer cells transfected with PRDX3/small interfering (Si)‑1 efficiently downregulated the expression of PRDX3 and thus decreased the growth of the SKOV3 cells in vitro and in vivo. Furthermore, the silencing of PRDX3 triggered cisplatin‑mediated apoptosis in the ovarian cancer cells, which may act through suppression of the NF‑κB signaling pathway. These data suggest a new mechanism by which the downregulation of PRDX3 enhances cisplatin‑induced ovarian cancer cell apoptosis. This mechanism may provide new evidence for the potential application of PRDX3‑siRNA in ovarian cancer therapy.

View Figures

View References

1	Wolf JK and Jenkins AD: Gene therapy for ovarian cancer (Review). Int J Oncol. 21:461–468. 2002.PubMed/NCBI
2	Felix AS, Stone RA, Bowser R, Chivukula M, Edwards RP, Weissfeld JL and Linkov F: Comparison of survival outcomes between patients with malignant mixed mullerian tumors and high-grade endometrioid, clear cell, and papillary serous endometrial cancers. Int J Gynecol Cancer. 21:877–884. 2011. View Article : Google Scholar
3	Lalwani N, Prasad SR, Vikram R, Shanbhogue AK, Huettner PC and Fasih N: Histologic, molecular, and cytogenetic features of ovarian cancers: implications for diagnosis and treatment. Radiographics. 31:625–646. 2011. View Article : Google Scholar : PubMed/NCBI
4	Ledermann J, Harter P, Gourley C, et al: Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 366:1382–1392. 2012. View Article : Google Scholar : PubMed/NCBI
5	Stańczyk M, Gromadzińska J and Wasowicz W: Roles of reactive oxygen species and selected antioxidants in regulation of cellular metabolism. Int J Occup Med Environ Health. 18:15–26. 2005.PubMed/NCBI
6	Okai Y, Sato EF, Higashi-Okai K and Inoue M: Potentiating effect of an endocrine disruptor, paranonylphenol, on the generation of reactive oxygen species (ROS) in human venous blood - association with the activation of signal transduction pathway. J UOEH. 29:221–233. 2007.
7	Moon HJ, Ko WK, Han SW, Kim DS, Hwang YS, Park HK and Kwon IK: Antioxidants, like coenzyme Q10, selenite, and curcumin, inhibited osteoclast differentiation by suppressing reactive oxygen species generation. Biochem Biophys Res Commun. 418:247–253. 2012. View Article : Google Scholar
8	Avni R, Cohen B and Neeman M: Hypoxic stress and cancer: imaging the axis of evil in tumor metastasis. NMR Biomed. 24:569–581. 2011.PubMed/NCBI
9	Morita M, Yano S, Yamaguchi T, Yamauchi M and Sugimoto T: Phenylacetic acid stimulates reactive oxygen species generation and tumor necrosis factor-α secretion in vascular endothelial cells. Ther Apher Dial. 15:147–150. 2011.PubMed/NCBI
10	Pak JH, Choi WH, Lee HM, et al: Peroxiredoxin 6 overexpression attenuates cisplatin-induced apoptosis in human ovarian cancer cells. Cancer Invest. 29:21–28. 2011. View Article : Google Scholar : PubMed/NCBI
11	Lowther WT and Haynes AC: Reduction of cysteine sulfinic acid in eukaryotic, typical 2-Cys peroxiredoxins by sulfiredoxin. Antioxid Redox Signal. 15:99–109. 2011. View Article : Google Scholar : PubMed/NCBI
12	Aran M, Ferrero DS, Pagano E and Wolosiuk RA: Typical 2-Cys peroxiredoxins - modulation by covalent transformations and noncovalent interactions. FEBS J. 276:2478–2493. 2009. View Article : Google Scholar : PubMed/NCBI
13	Rhee SG and Woo HA: Multiple functions of peroxiredoxins: peroxidases, sensors and regulators of the intracellular messenger H₂O₂, and protein chaperones. Antioxid Redox Signal. 15:781–794. 2011. View Article : Google Scholar : PubMed/NCBI
14	Lin H, Lu JP, Laflamme P, et al: Inter-related in vitro effects of androgens, fatty acids and oxidative stress in prostate cancer: A mechanistic model supporting prevention strategies. Int J Oncol. 37:761–766. 2010.
15	Flohé L, Budde H and Hofmann B: Peroxiredoxins in antioxidant defense and redox regulation. Biofactors. 19:3–10. 2003.
16	Qiao B, Wang J, Xie J, Niu Y, Ye S, Wan Q and Ye Q: Detection and identification of peroxiredoxin 3 as a biomarker in hepatocellular carcinoma by a proteomic approach. Int J Mol Med. 29:832–840. 2012.PubMed/NCBI
17	Kim YS, Lee HL, Lee KB, et al: Nuclear factor E2-related factor 2 dependent overexpression of sulfiredoxin and peroxiredoxin III in human lung cancer. Korean J Intern Med. 26:304–313. 2011. View Article : Google Scholar : PubMed/NCBI
18	Basu A, Banerjee H, Rojas H, et al: Differential expression of peroxiredoxins in prostate cancer: consistent upregulation of PRDX3 and PRDX4. Prostate. 71:755–765. 2011. View Article : Google Scholar : PubMed/NCBI
19	Dai Z, Yin J, He H, et al: Mitochondrial comparative proteomics of human ovarian cancer cells and their platinum-resistant sublines. Proteomics. 10:3789–3799. 2010. View Article : Google Scholar : PubMed/NCBI
20	Lee S, Kwon H, Jeong K and Pak Y: Regulation of cancer cell proliferation by caveolin-2 down-regulation and re-expression. Int J Oncol. 38:1395–1402. 2011.PubMed/NCBI
21	Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin. 58:71–96. 2008. View Article : Google Scholar
22	Bookman MA: Developmental chemotherapy and management of recurrent ovarian cancer. J Clin Oncol. 21(10 Suppl): 149s–167s. 2003. View Article : Google Scholar : PubMed/NCBI
23	Young TW, Mei FC, Yang G, Thompson-Lanza JA, Liu J and Cheng X: Activation of antioxidant pathways in ras-mediated oncogenic transformation of human surface ovarian epithelial cells revealed by functional proteomics and mass spectrometry. Cancer Res. 64:4577–4584. 2004. View Article : Google Scholar
24	Oiso S, Ikeda R, Nakamura K, Takeda Y, Akiyama S and Kariyazono H: Involvement of NF-κB activation in the cisplatin resistance of human epidermoid carcinoma KCP-4 cells. Oncol Rep. 28:27–32. 2012.
25	Sethi G, Sung B and Aggarwal BB: Nuclear factor-kappaB activation: from bench to bedside. Exp Biol Med (Maywood). 233:21–31. 2008. View Article : Google Scholar : PubMed/NCBI